Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
Authors' conclusion
iGlarLixi showed consistent efficacy and safety across all age and disease duration subgroups in Asian people with uncontrolled T2D, including older individuals and those with longstanding disease.
Study context
- Population
- Asian people with T2D uncontrolled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin ± oral antidiabetic drugs (LixiLan-L-CN); subgroups by baseline age (<65, ≥65 years) and T2D duration
- Comparison
- iGlarLixi vs iGlar or lixisenatide (Lixi) alone
- Primary endpoint
- HbA1c change from baseline in subgroups by age and T2D duration
- Follow-up
- Week 24 (LixiLan-O-AP) or 30 (LixiLan-L-CN)
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
HbA1c reduction across age and T2D duration subgroups · week 24 or 30
- HbA1c reductions consistently greater with iGlarLixi vs iGlar or Lixi across all subgroups, incl. aged ≥65 years and T2D for ≥15 or ≥20 years
Further findings
Composite of HbA1c <7% (<53.0 mmol/mol) without weight gain or hypoglycaemia
- Greater proportions achieved composite with iGlarLixi vs iGlar or Lixi, regardless of age or T2D duration
Safety
- Hypoglycaemia incidence similar with iGlarLixi vs iGlar across most subgroups
- Gastrointestinal disorders lower with iGlarLixi vs Lixi in all subgroups
Original publication
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials. Diabetes Obes Metab. Published 3 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →